SCOTUS overturn of Chevron doctrine opens a Pandora's box for biopharma industry, expert says
Fierce Pharma
AUGUST 27, 2024
In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services. An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview.
Let's personalize your content